Other
Ondansetron
1
Pipeline Programs↗
5
Active Trials↗
7
Companies Involved↗
Ondansetron is an early-stage landscape with 1 program across 7 companies. The most active players are Novartis, Mylan Pharmaceuticals Inc, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
56
clinical trials
Completed42 · 75%
Unknown status5 · 9%
Terminated3 · 5%
Active, not recruiting2 · 4%
Enrolling by invitation1 · 2%
Withdrawn1 · 2%
Other2 · 4%
Clinical Trials
Trial Activity
56 trials
Ondansetron Augmentation in Treatment-resistant OCD
Completed·—·Phase 4·NCT01303536·21 enrolled
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
Completed·—·Phase 2·NCT01377662·30 enrolled
Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fasting Condition
Completed·—·Phase 1·NCT01511705·26 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)